We are a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including […]

  We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Our […]

  Although we may pursue an acquisition opportunity in any business or industry, we intend to focus on opportunities in the technology sector, particularly companies pursuing a Software-as-a-Service, or SaaS, model, which we believe will deliver strong risk-adjusted returns for our investors.

  We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH. NASH is a severe form of NAFLD, characterized by inflammation […]

  We currently intend to concentrate our efforts in identifying businesses in the financial services industry with an equity value of approximately $500 million to $1.5 billion, with particular emphasis on businesses that are providing or changing technology for traditional financial services (“FinTech”), asset and wealth management, and specialty finance companies.

We are a digital cinema company that designs, manufactures, integrates, installs and distributes a full suite of proprietary and custom-designed equipment as well as other off-the-shelf cinema products needed for contemporary cinema requirements. We also offer single-source solutions for cinema design, procurement, installation and service to the creative and production communities for screening, digital intermediate […]

Our mission is to make it easy for real estate agents to do business and empower them to achieve their dreams. We are aligned with the agents on our platform and our products and services are designed to help them grow and succeed. Through innovative use of mobile internet, cloud and big data, we are […]

  Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a business in the legal cannabis industry.

  While we may pursue an initial business combination target in any industry or geographic location, we intend to focus our search on companies in the aerospace , defense and communications industries with enterprise valuations in the range of $350 million to $1 billion.

  We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Our lead product candidate OC-01 (varenicline), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease […]